Psychedelic Therapy Training for Psychologists in Canada: What Registered Psychologists Need to Know

Registered psychologists in Canada occupy a distinct position within psychedelic-assisted therapy. Doctoral-level assessment authority, supervised-hour requirements, and scope-of-practice rules under each provincial psychology college shape what training a psychologist needs, where it counts toward continuing education, and how it integrates with prescribing physicians and patient care teams.

Key takeaways

• Alberta is the only Canadian province with a formal psychology-college guideline for psychedelic-assisted psychotherapy (CAP Practice Guideline, June 2025).
• Psychologists do not prescribe psychedelics in any province; psilocybin and MDMA are accessible only through Health Canada's Special Access Program (SAP) under physician oversight, and ketamine is prescribed off-label by physicians.
• The CPA Continuing Education Approval Programme governs how CE hours from training providers are credited; the provider Journey Centres, TheraPsil, and Numinus are all listed CPA-approved sponsors.
• Master's-level scope varies by province: Alberta and Ontario register master's-level psychologists (or psychological associates) for independent practice; British Columbia and Quebec restrict the title "Psychologist" to doctoral-level registrants.
• Specialized PAT training, supervised hours, and ongoing peer consultation are required across colleges before a psychologist takes on PAT work — see the CAP guideline and your provincial body for jurisdiction-specific rules.

Why psychologists are uniquely positioned for psychedelic-assisted therapy

Doctoral-level training in psychology already covers several competencies the field requires before a clinician sits with a patient through preparation, dosing, and integration. Standardized assessment, formulation of complex trauma, outcome measurement, and supervision are part of the registration pathway in every province.

Therapeutic alliance is the single most-replicated outcome predictor across psychedelic-assisted trials. In a 2024 randomized waiting-list trial in major depressive disorder, "stronger total alliance one week after the final psilocybin session predicted depression scores at 4 weeks, 3 months, 6 months, and 12 months post-intervention" (Levin et al., 2024). The 2018 meta-analytic synthesis of 295 psychotherapy studies (over 30,000 patients) found an alliance–outcome correlation of r = .278 across modalities (Flückiger et al., 2018), and a 2022 sub-analysis of psilocybin therapy for depression confirmed that alliance strength predicted both the quality of the acute experience and final QIDS depression scores (Murphy et al., 2022).

Psychometric administration is a second area where psychologist training translates directly. The Phase 3 MDMA-assisted therapy trials (MAPP1 and MAPP2) used the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) administered by blinded independent assessors (Mitchell et al., 2021; Mitchell et al., 2023). Psilocybin trials in major depressive disorder use the MADRS as the primary endpoint (Goodwin et al., 2022; Raison et al., 2023). Doctoral-level psychologists are among the few Canadian regulated practitioners who routinely administer, score, and interpret these instruments without external oversight.

A 2025 Lancet Psychiatry systematic review found that "completeness of information reported about [psychological] interventions was mostly low" across psychedelic trials (Seybert et al., 2025) — pointing to a field-level need for the kind of structured documentation and protocol fidelity that psychologists are trained to provide. Therapist adherence to the MDMA-AT manual averaged 94.5% across MAPS multisite training studies in the US and Canada (Wang et al., 2021) — fidelity is measurable, and it is trainable.

The Canadian regulatory landscape for psychologist practitioners (2025–2026)

Each Canadian province regulates psychology independently. As of May 2026, only one provincial psychology college has issued formal guidance on psychedelic-assisted psychotherapy.

Alberta — College of Alberta Psychologists (CAP)

The CAP issued its Practice Guideline: Psychedelic-Assisted Psychotherapy on June 30, 2025 — the first formal guideline from any Canadian psychology college. It applies to all CAP registrants, including doctoral and master's-level Registered Psychologists and Provisional Psychologists.

CAP's guideline operates within Alberta's Mental Health Services Protection Regulation (Alta Reg 114/2021), which requires community-based psychedelic-assisted psychotherapy to be "provided within a CPSA-accredited medical facility by a psychiatrist or a physician in consultation with a psychiatrist." Therapists working within a licensed PAPT service must be authorized to perform the restricted activity of psychosocial intervention and be a regulated member of CAP, ACSW, the College of Physicians and Surgeons of Alberta, an Alberta nursing college, or the Alberta College of Occupational Therapists.

Designated psychedelics under Alberta law include psilocybin, psilocin, MDMA, LSD, mescaline, DMT, 5-MeO-DMT, and ketamine when used in a psychedelic dose within a PAPT context. Only a psychiatrist may prescribe a designated psychedelic drug.

British Columbia — College of Health and Care Professionals of BC (CHCPBC)

CPBC was absorbed into the CHCPBC on June 28, 2024, with the Health Professions and Occupations Act in force April 1, 2026 and the Professional & Quality Practice Program launching fall 2026. The "Psychologist" title in British Columbia is restricted to doctoral-level registrants; School Psychologists registered at the master's level practice within a defined educational scope and would not provide PAP psychotherapy under that title.

CHCPBC has not issued a PAP-specific guideline as of May 2026. The BC College of Social Workers practice-guidance document (applicable by analogy) confirms that PAP outside Health Canada clinical trials or SAP "is not authorized currently." Psychologists may provide preparation and integration psychotherapy within those legal frameworks.

Ontario — College of Psychologists and Behaviour Analysts of Ontario (CPBAO)

Ontario registers Psychologists at the doctoral level and Psychological Associates at the master's level for independent practice. CPBAO has not issued PAP-specific guidance. CRPO (the regulator for registered psychotherapists, not psychologists) has stated it is "in the process of developing guidance" for PAP — psychologists in Ontario should apply general scope-of-practice and competence rules.

CPBAO's continuing professional development requirement is 50 hours per two-year cycle, with 10 hours of ethics, 5 hours of EDI, and a 10-hour cap per single program. PAT training can count toward Sections A and B of the CPD plan.

Manitoba — Psychological Association of Manitoba (PAM)

PAM (also known as CPMB) registers C.Psych psychologists (doctoral) and Psychological Associates (master's, independent practice). No PAP-specific guideline has been published. Psychologists work within the federal SAP framework and general competence rules. Contact PAM directly for the current CE policy.

Quebec — Ordre des psychologues du Québec (OPQ)

Quebec is unique in Canada: only doctoral graduates hold the "Psychologist" title, and that title encompasses the practice of psychotherapy without a separate permit. The OPQ requires 90 hours of continuing education over five years for psychologists practising psychotherapy. OPQ maintains a recognized-CE catalogue. TheraPsil is approved by OPQ for 30 CE hours, and Numinus is approved for OPQ CE credits.

OPQ has not issued PAP-specific guidance as of May 2026. Psychologists in Quebec should treat psilocybin and MDMA as accessible only through Health Canada SAP, with ketamine available off-label through physicians.

Federal — Health Canada Special Access Program

The Health Canada SAP framework governs all access to psilocybin and MDMA outside clinical trials. Health Canada's December 2022 risk-management addendum requires that "therapists must be properly trained on evidence-informed protocols for psychedelic-assisted psychotherapy, and be licensed to provide psychotherapy by a regulatory body," that "during drug administration, at least two therapists should be present," and that a licensed physician provides medical oversight.

The prescribing physician submits the SAP application; psychologists do not apply directly. PsyCan reported in September 2025 that SAP approval rates declined sharply through 2025 — affecting the patient pipeline for psychologists working in PAP teams.

What "competency" means before you practise

Across provincial colleges, the threshold for taking on PAP work involves four components: specialized training, supervised clinical hours, post-licensure clinical experience, and ongoing peer consultation. The CAP guideline, the BCCSW analog guidance, and Health Canada's "licensed by a regulatory body" requirement all converge on the same picture.

Specialized training in psychedelic-assisted psychotherapy means a defined curriculum covering screening and assessment, set and setting, informed consent, drug pharmacology and adverse-event recognition, the structure of preparation, the dosing session itself, and integration. Hartogsohn (2018) frames the clinical reason: "the psychological context (set) and sociocultural context (setting) of a psychedelic experience are considered crucial because their meaning is significantly multiplied by the effects of the drugs" (Hartogsohn, 2018).

Phelps's 2017 framework — empathetic abiding presence, trust enhancement, spiritual intelligence, pharmacological knowledge, ethical integrity, and proficiency in complementary techniques (Phelps, 2017) — remains the most-cited competency map. Tai et al. (2021) translated it into an FDA-reviewed manualized training program that qualified 65 therapists across the US, Canada, and Europe for Phase 2b psilocybin trials in treatment-resistant depression (Tai et al., 2021).

For doctoral-level psychologists, several Phelps domains (ethical integrity, complementary technique proficiency, presence) are already part of registration training — which shortens the incremental coursework required, but does not eliminate it.

CE-credit recognition: what counts toward your annual requirements

The Canadian Psychological Association's CE Approval Programme operates as a sponsorship system: approved sponsors can issue CE certificates that registrants apply to their college's CPD requirement. As of the 2025 CPA sponsor list, the provider Journey Centres (Calgary, AB), TheraPsil (Vancouver, BC), TheraPsil NPO, and Numinus Wellness (Vancouver, BC) are all CPA-approved CE sponsors (CPA Approved Sponsors).

The college-by-college mapping that matters in practice:

The registrant is responsible for filing the right CE certificate with the right college. CPA approval and OPQ recognition are separate processes; an OPQ-recognized program is not automatically CPA-approved, and a CPA-approved program is not automatically OPQ-recognized. Confirm the specific accreditation that matches your registering body before enrolling.

The training programs available to Canadian psychologists (2026)

For Canadian psychologists evaluating these programs, the relevant questions are: which program holds CE accreditation with my college, how many hours, what is the substance focus (ketamine entry point vs. psilocybin/MDMA SAP context), and how does the program align with my existing scope and clinical experience.

How to choose the right program as a psychologist

Three filters narrow the choice quickly.

Is CPA, OPQ, or CCPA approval a requirement for your college? If you register with OPQ in Quebec, your CE hours must come from OPQ-recognized programs — TheraPsil's 30 OPQ hours are a documented option. If you register with CPBAO in Ontario, CPA-approved sponsorship satisfies the requirement. Verify each course with your college before paying.

Ketamine versus psilocybin/MDMA as a starting point. Ketamine is currently legally available in Canada through physician prescribing (off-label). Psilocybin and MDMA require Health Canada SAP applications submitted by physicians and have lower current approval rates. Psychologists who want to start practising PAP within months — rather than years — typically train on ketamine first, then add psilocybin and MDMA training as the regulatory environment evolves. ATMA CENA's KAT Immersive Experience is a 3-day in-person experiential add-on for psychologists already enrolled in the Clinical Pathway.

Explore the Clinical Pathway for the full curriculum and cohort dates.

After training: building a psychedelic-assisted practice

Psychologists do not work alone in PAP. Health Canada's SAP framework requires physician medical oversight; Alberta's PAPT regulation requires psychiatric supervision and a CPSA-accredited facility; ketamine prescribing is by a physician. Building a practice means assembling — or joining — a team.

Documentation standards for psychologists in PAP include consent forms that disclose the legal status of the substance (SAP, off-label, or clinical trial), the role of the physician versus the psychologist on the team, the limits of confidentiality during the active dosing phase, and the conditions under which the active session may be paused or terminated. Trauma-informed care is a documented evidence-based framework in PAP research (Modlin et al., 2024) — the integration of CPT, PE, EMDR, and somatic interventions that psychologists already use translates directly.

Integration therapy is where psychologists' existing competencies most directly apply. The Psychedelic Harm Reduction and Integration model (Gorman et al., 2021) and the EMBARK transdiagnostic, trans-drug framework (Brennan & Belser, 2022) are compatible with CBT, ACT, psychodynamic, and somatic orientations. Both frameworks assume the psychologist's role extends past the dosing session — preparing the patient, supporting them through the experience, and integrating the material over weeks to months afterwards.

ATMA CENA's coordinated care model is one practice-integration option for trained psychologists in private practice: clinic-network access, referral relationships, and supervised clinical hours without leaving private practice or building a new facility.

ATMA CENA's Clinical Pathway: designed for licensed psychologists

ATMA CENA's Clinical Pathway bundles three components for licensed therapists practising — or planning to practise — PAP:

• Psychedelic-Assisted Therapy Foundations (14 hours / 14 CE; CAD $800): asynchronous online module covering pharmacology, history, ethics, and the legal frameworks across Canada.
• Applied Clinical Practice in Psychedelic Therapy (55 hours / 55 CE; CAD $5,400 includes Supervised Learning Lab): asynchronous online + 3 live Q&A sessions + 2 Self-Care Sundays.
• Supervised Learning Lab (8 hours / 8 CE; included in Applied Clinical bundle): 4 live virtual sessions in groups of 8 participants — applied case work and supervision.

Total Clinical Pathway: 69 CE hours at CAD $6,200 (Foundations standalone) or CAD $5,400 if Applied Clinical and SLL are taken as a bundle. Optional: KAT Immersive Experience (CAD $2,400) — a 3-day in-person weekend in Calgary for psychologists who want experiential ketamine-context training before clinical practice.

Frequently asked questions

Can a registered psychologist prescribe psychedelics in Canada?

No. Psilocybin and MDMA are accessible only through Health Canada's Special Access Program (SAP), applied for and prescribed by physicians. Ketamine is prescribed off-label by physicians. Psychologists work alongside prescribers — they do not prescribe.

Does completing PAT training mean I can practise legally?

No. Training is one component. You also need: (a) confirmation from your provincial psychology college that PAP is within your scope under the relevant guideline (or, where no guideline exists, that general competence and scope rules permit it), (b) documented supervised clinical hours, and (c) a working relationship with a prescribing physician — and in Alberta, a CPSA-accredited facility.

Which province has the clearest framework for psychologist practitioners?

Alberta. The CAP June 2025 Practice Guideline is the only formal Canadian psychology-college PAP guideline. Other provinces operate under general competence rules and the federal SAP framework.

Is TheraPsil's CPA CE approval accepted by all provincial colleges?

CPA (Canadian Psychological Association) approval is generally accepted by colleges that recognize CPA sponsorship. OPQ recognition is separate; TheraPsil holds 30 OPQ hours specifically. Always verify with your registering college before claiming hours.

How long does it take from starting training to seeing PAP clients?

For ketamine-assisted therapy: typically 6–12 months from training start to first supervised case, depending on access to a prescribing physician. For psilocybin/MDMA: dependent on Health Canada SAP approval rates and patient eligibility — practitioners report 12–24 or more months from training start to first SAP case under current approval conditions.

What is the difference between doctoral and master's-level scope for PAP?

In Alberta and Ontario, both register practitioners for independent practice — both can take on PAP work within their college's scope. In British Columbia and Quebec, the "Psychologist" title is doctoral-only; master's-level practitioners hold different titles (School Psychologist in BC; Psychotherapist with separate OPQ permit in Quebec). The PAP work itself is open to multiple regulated professions, but the title and scope distinction matters when documenting your role.

Are CPSA-accredited facilities required everywhere in Canada for psilocybin/MDMA work?

No. The CPSA accreditation requirement is specific to Alberta under the Mental Health Services Protection Regulation. Other provinces operate within Health Canada's SAP framework without an equivalent provincial facility licence requirement. Verify provincial requirements before structuring a practice.

How does this training affect my malpractice coverage?

Speak with your insurer. Most psychology professional liability insurers in Canada require pre-approval for PAP work; some require completion of an accredited training program plus supervised hours; some exclude PAP entirely. Verify before practising.

Can I provide supervision for non-psychologist PAP support workers?

This depends on provincial scope rules and the supervised practitioner's regulatory body. In Alberta, the CAP guideline addresses supervision of support staff during the active phase. Other provinces handle this through general scope rules.

What if I am a Provisional Psychologist (CAP) — can I do PAP work during provisional registration?

The CAP guideline applies to all registrants including provisionals. Provisional psychologists may work within a licensed PAPT service under supervision, with the requisite specialized training, the same way they work in other clinical contexts.

Sources

1. CAP Practice Guideline: Psychedelic-Assisted Psychotherapy (June 2025): https://www.cap.ab.ca/Portals/0/adam/Content/fQCpza4q7EGXC_psrgnCvA/Link/Psychedelic-Assisted%20Psychotherapy%20-%20June%202025.pdf
2. CAP Continuing Competence: https://www.cap.ab.ca/continuing-competence
3. CHCPBC Psychologists Registrants: https://chcpbc.org/registrants/psychologists/
4. CPBAO Continuing Professional Development: https://cpbao.ca/members/quality-assurance/continuing-professional-development/
5. Psychological Association of Manitoba (PAM/CPMB): https://www.cpmb.ca/
6. Ordre des psychologues du Québec: https://www.ordrepsy.qc.ca/english
7. Health Canada SAP Notice — Psychedelic-Assisted Psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
8. CPSA Psychedelic-Assisted Psychotherapy Facility Accreditation: https://cpsa.ca/facilities-clinics/accreditation/psychedelic-assisted-psychotherapy/
9. CPSA Ketamine Guidance (March 2026): https://cpsa.ca/wp-content/uploads/2026/03/CPSA_Ketamine-Guidance_March-2026.pdf
10. PsyCan SAP Decline (September 2025): https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
11. CPA Continuing Education Approval Programme: https://cpa.ca/professionaldevelopment/approval/
12. CPA Approved CE Sponsors: https://cpa.ca/professionaldevelopment/sponsors/
13. BCCSW Practice Guidance — Psychedelic-Assisted Psychotherapy: https://bccsw.ca/for-registrants/standards-scope-of-practice/practice-guidance/practice-guidance-document-for-registrants-psychedelic-assisted-psychotherapy/
14. Alberta Psychedelic Drug Treatment Service Provider Licensing: https://www.alberta.ca/psychedelic-drug-treatment-service-provider-licensing
15. Murphy R, et al. (2022). Therapeutic alliance and rapport in psilocybin therapy. Front Pharmacol. https://pubmed.ncbi.nlm.nih.gov/35431912/
16. Levin AW, et al. (2024). Therapeutic alliance and clinical outcomes in psilocybin trial. PLoS One. https://pubmed.ncbi.nlm.nih.gov/38483940/
17. Flückiger C, et al. (2018). Alliance in adult psychotherapy meta-analytic synthesis. Psychotherapy. https://pubmed.ncbi.nlm.nih.gov/29792475/
18. Hovmand OR, et al. (2024). Patient-reported outcome measures in psychedelic research. J Psychopharmacol. https://journals.sagepub.com/doi/10.1177/02698811231200019
19. Seybert C, et al. (2025). Reporting quality of psychological interventions in psychedelic treatments. Lancet Psychiatry. https://pubmed.ncbi.nlm.nih.gov/39667373/
20. Goodwin GM, et al. (2022). Single-dose psilocybin for treatment-resistant depression. N Engl J Med. https://pubmed.ncbi.nlm.nih.gov/36322843/
21. Raison CL, et al. (2023). Psilocybin for major depressive disorder. JAMA. https://pubmed.ncbi.nlm.nih.gov/37651119/
22. Carhart-Harris RL, et al. (2017). Psilocybin TRD fMRI mechanisms. Sci Rep. https://pubmed.ncbi.nlm.nih.gov/29030624/
23. Mitchell JM, et al. (2021). MDMA-assisted therapy Phase 3 (MAPP1). Nat Med. https://pubmed.ncbi.nlm.nih.gov/33972795/
24. Mitchell JM, et al. (2023). MDMA-assisted therapy Phase 3 (MAPP2). Nat Med. https://pubmed.ncbi.nlm.nih.gov/37709999/
25. Wang JB, et al. (2021). MAPS multisite open-label MDMA-AT studies. J Humanist Psychol. https://journals.sagepub.com/doi/full/10.1177/00221678211023663
26. Kang MJY, et al. (2022). Ketamine antidepressant mechanisms systematic review. Front Psychiatry. https://pubmed.ncbi.nlm.nih.gov/35546951/
27. Swainson J, et al. (2021). CANMAT racemic ketamine recommendations. Can J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/33174760/
28. Drozdz SJ, et al. (2022). Ketamine-assisted psychotherapy review. J Pain Res. https://pubmed.ncbi.nlm.nih.gov/35734507/
29. Chrenek C, et al. (2024). Edmonton community ketamine program. Front Psychiatry. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1283733/full
30. Hartogsohn I (2018). Meaning-enhancing properties of psychedelics. Front Neurosci. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2018.00129/full
31. Phelps J (2017). Competencies for psychedelic therapist training. J Humanist Psychol. https://journals.sagepub.com/doi/abs/10.1177/0022167817711304
32. Tai SJ, et al. (2021). Therapist training program for psilocybin TRD trials. Front Psychiatry. https://pubmed.ncbi.nlm.nih.gov/33643087/
33. Gorman I, et al. (2021). Psychedelic harm reduction and integration model. Front Psychol. https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2021.645246/full
34. Brennan W, Belser AB (2022). EMBARK transdiagnostic PAP model. Front Psychol. https://pubmed.ncbi.nlm.nih.gov/35719571/
35. Modlin NL, et al. (2024). Trauma-informed care in psychedelic therapy research. Neuropsychiatr Dis Treat. https://pubmed.ncbi.nlm.nih.gov/38268571/
36. TheraPsil Psilocybin Therapy Training: https://therapsil.ca/psilocybin-therapy-training/

Related articles in this cluster

• Psychedelic Therapy Training in Canada
• Ketamine-Assisted Psychotherapy Training in Canada
• Psychedelic Therapy Training for Physicians
• Psychedelic Therapy Training for Counsellors
• Psychedelic Therapy Training for Psychotherapists
• Which Psychedelic Therapy Training Pathway Is Right for Me?
• Find care near you

Last updated: 2026-05-05